Verrica Pharmaceuticals Price to Free Cash Flow Ratio 2017-2024 | VRCA

Verrica Pharmaceuticals price to free cash flow ratio from 2017 to 2024. Price to free cash flow ratio can be defined as

Verrica Pharmaceuticals Price to Free Cash Flow Ratio 2017-2024 | VRCA

Verrica Pharmaceuticals price to free cash flow ratio from 2017 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.8B
Takeda Pharmaceutical (TAK)$43.8B
Merck (MKKGY)$21B
Astellas Pharma (ALPMY)$20.2B
Sandoz Group AG (SDZNY)$19.8B
United Therapeutics (UTHR)$18.3B
Summit Therapeutics (SMMT)$15.8B
Neurocrine Biosciences (NBIX)$12.7B
Shionogi (SGIOY)$12.5B
Catalent (CTLT)$10.8B
Madrigal Pharmaceuticals (MDGL)$7.6B
Jazz Pharmaceuticals (JAZZ)$7.6B
Orion OYJ (ORINY)$6.8B
Corcept Therapeutics (CORT)$6.2B
Ionis Pharmaceuticals (IONS)$6.2B
Crinetics Pharmaceuticals (CRNX)$4.9B
PTC Therapeutics (PTCT)$3.4B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.9B
Arrowhead Pharmaceuticals (ARWR)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2.2B
Recursion Pharmaceuticals (RXRX)$2B
Centessa Pharmaceuticals (CNTA)$1.9B
Harrow (HROW)$1.9B
Ocular Therapeutix (OCUL)$1.7B
Xencor (XNCR)$1.7B
ARS Pharmaceuticals (SPRY)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B